Oregovomab - OncoQuest
Alternative Names: Anti-CA125-monoclonal-antibody-B43-13-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-AltaRex; Anti-idiotype-ovarian-cancer-vaccine-CA125; Mab B43.13; Monoclonal antibody B43.13; OvaRex; Ovarian-cancer-vaccine-AltaRexLatest Information Update: 28 Aug 2024
At a glance
- Originator AltaRex
- Developer National Cancer Centre (Singapore); National Cancer Institute (USA); OncoQuest; University of Nebraska Medical Center; Yonsei University
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase II Pancreatic cancer
Most Recent Events
- 23 Aug 2024 CanariaBio completes the enrollment in phase II trials in Peritoneal cancer (Combination therapy, Late-stage disease, Newly diagnosed, Neoadjuvant therapy) in India (IV) (NCT05605535)
- 31 May 2024 Adverse events and efficacy data from a phase II FLORA-4 trial in Ovarian cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.